FDA Approves Rinvoq for Giant Cell Arteritis Based on the results of the SELECT-GCA study, the US FDA has approved upadacitinib (Rinvoq or UPA) for the treatment of adults with giant cell arteritis (GCA), also known as temporal arteritis. This is the 9th FDA approved indication https://t.co/gPTwnR2VLw